Recently, the covid-19 epidemic situation in China is more severe and complex. China Securities News reporter learned that a number of Sci-tech Innovation Board biomedical companies are still fully engaged in R & D and production to continuously meet the needs of epidemic prevention and control.
Since the covid-19 epidemic, Kechuang board biomedical company has given full play to its professional advantages in innovative drugs, vaccines and in vitro diagnosis, carried out emergency research, actively fought on the front line of anti epidemic, and bloomed hard scientific and technological strength in “war epidemic” one after another.
innovative drugs: keep up with the development of world cutting-edge technologies
Up to now, more than 10 Kechuang board biomedical companies have invested in the R & D and production of specific drugs and APIs.
Shanghai Junshi Biosciences Co.Ltd(688180) , located in Pudong New Area, Shanghai, as a pioneer of local innovative pharmaceutical companies, has invested in the research and development of anti epidemic drugs at the beginning of the epidemic. At present, a R & D pipeline consisting of a variety of anti COVID-19 neutralizing antibody drugs and small molecule oral drugs has been formed.
Shanghai Junshi Biosciences Co.Ltd(688180) Board Secretary Chen Yingge told China Securities News that the company has several R & D centers to coordinate and undertake the R & D work of research projects. At present, the R & D and production of the company are still advancing in an orderly manner. For example, the clinical application of covid-19 oral drug vv116 is being carried out in many centers around the world.
It is reported that based on the positive results of vv116 in the phase I study, Shanghai Junshi Biosciences Co.Ltd(688180) has initiated an international multicenter, double-blind, randomized, placebo-controlled, phase II / III clinical study with partners for mild to moderate covid-19 patients. In addition, an international multicenter, randomized, double-blind, controlled phase III clinical study to evaluate the efficacy and safety of vv116 in patients with moderate and severe covid-19 is ongoing.
As a non-profit enterprise without product approval at the time of listing, Sinocelltech Group Limited(688520) actively invested in the research and development of covid-19 neutralizing antibody after listing. The company is also simultaneously developing recombinant covid-19 virus alpha + beta mutant s trimer protein vaccine. Existing research shows that the product can stimulate stronger and wider spectrum neutralizing antibody titer of mutant strains, and can more effectively resist the infection risk of mutant strains.
vaccine: building the first barrier against epidemic
In the severe and complex situation of the epidemic, the research, development and vaccination of vaccines have played a key role in combating the epidemic and blocking the transmission. Since the outbreak of the epidemic, domestic vaccine R & D enterprises have worked against every minute to build a solid barrier against the epidemic.
Innovative vaccine leader Cansino Biologics Inc(688185) has been continuously put into vaccine research and development and production in recent years. It is reported that the recombinant New Coronavirus vaccine (adenovirus type 5), jointly developed by the company and the Institute of biotechnology, has been listed in several countries and is approved by many countries such as China, Malaysia and Indonesia as the strengthening needle. It has become the first COVID-19 vaccine approved by China for sequential immunization.
In addition, Cansino Biologics Inc(688185) also further developed inhaled covid-19 vaccine and mRNA covid-19 vaccine. At present, its inhaled covid-19 vaccine is steadily promoting clinical trials. Recently, Cansino Biologics Inc(688185) said on the interactive platform that the company will actively make relevant preparations so that the supply of inhaled covid-19 vaccine products can be realized as soon as possible after being approved, so as to provide protection for the people and establish an immune barrier.
Industry insiders believe that the inhalation covid-19 vaccine product adopts the administration mode of atomization inhalation, which can stimulate mucosal immune response and provide additional protection in respiratory mucosal tissue. This immunization method can not be achieved through intramuscular injection, which is expected to provide new ideas for further epidemic prevention and control.
in vitro diagnosis: efficient scouts racing against the virus
In the race against the epidemic, screening and testing are essential. At present, many companies in the in vitro diagnosis industry of scientific innovation board have developed covid-19 nucleic acid detection reagent, and innovated and launched a series of scientific and technological anti epidemic products such as rapid nucleic acid detection equipment and respiratory disease joint detection reagent.
Sansure Biotech Inc(688289) developed a rapid nucleic acid detection system, which broke the bottleneck of application scenarios such as professional laboratories and promoted nucleic acid detection from the previous “hour level” to “minute level” with higher sensitivity. At the same time, Sansure Biotech Inc(688289) , Shanghai Zj Bio-Tech Co.Ltd(688317) , Jiangsu Bioperfectus Technologies Co.Ltd(688399) and other companies have also developed mobile nucleic acid detection vehicles, which cover the whole process of sample collection, automatic sample pretreatment, nucleic acid extraction, nucleic acid detection and final report issuance, transforming the traditional and immovable PCR laboratory into a movable nucleic acid detection base.
Recently, relevant departments decided to take antigen detection as an auxiliary of nucleic acid detection to help rapid screening. So far, the State Food and drug administration has approved the listing of 20 covid-19 antigen self-test reagents, of which 5 are from science and Innovation Board companies.
Zhejiang Orient Gene Biotech Co.Ltd(688298) is one of them. According to public information, Zhejiang Orient Gene Biotech Co.Ltd(688298) covid-19 antigen detection reagent took the lead in fully promoting its use in the European market in July 2020, obtained market access from the US FDA at the end of December 2021, and recently obtained market access from Japan. On March 15, Zhejiang Orient Gene Biotech Co.Ltd(688298) covid-19 antigen detection reagent obtained the registration certification of Chinese products.
Zhejiang Orient Gene Biotech Co.Ltd(688298) relevant people told reporters, “As soon as we got the certificate, the company helped China’s epidemic prevention and donated millions of people. At the same time, the company immediately started supporting China’s production capacity, tried its best to overcome the production capacity bottleneck and meet the needs of China’s epidemic prevention and control to the greatest extent. At present, the company’s daily production capacity of covid-19 antigen detection reagent is 18 million people. Recently, the company has quickly supplied tens of millions of covid-19 antigen detection reagents to Shanghai and other places.”
